Provigate, Inc.

Provigate (株式会社Provigate) is a Tokyo-based medical technology company developing low- and non-invasive, low-cost home self-monitoring services for blood-sugar management. Its stated mission is to reduce the stigma around diabetes through a combination of sensing technology and software, and its stated vision is to become a company that empowers people with diabetes and those at elevated risk. The company frames poor adherence to lifestyle change not as a matter of willpower but as a technology problem, citing three shortcomings of today's home blood glucose meters — pain, cost and complexity — and noting that in Japan self-monitoring of blood glucose is reimbursed mainly for insulin users, who represent under about 10% of people with diabetes.

The technical premise is a re-definition of the role of glycated albumin (GA). Where HbA1c reflects average blood glucose over one to two months and therefore responds slowly to behavior change, GA — glycated serum albumin — has a half-life of roughly 17 days and reflects average glucose over roughly the preceding week, also picking up short-term glucose variability and the frequency of postprandial hyperglycemia. Provigate proposes measuring GA weekly at home as a short feedback loop ("quiz") on diet, exercise and medication, rather than using it only as an adjunct to HbA1c at periodic clinic visits.

Development is organized around three projects: a mail-in GA test in which a small fingertip blood or saliva sample is stably shipped to a testing center; a point-of-care (POCT) GA test for simple weekly measurement at home; and an empowerment app for users paired with a remote monitoring dashboard for healthcare professionals. Results are returned to the user's smartphone app. The company states these products and services began a phased launch from July 2023.

Founding story

CEO Koshin Sekimizu holds a bachelor's degree from the University of Tokyo Faculty of Science and a doctorate from its Graduate School of Science (Department of Biological Sciences), and worked at Corporate Directions and in private equity before meeting Toshiya Sakata, now an outside director, and co-founding the company with him. A precursor to the company's work was a 2012 JST START project on semiconductor biosensing for non-invasive diagnostics led by Sakata, described as pre-dating Provigate's founding.

Business model

Provigate develops and supplies a home blood-sugar self-monitoring service combining GA measurement (mail-in laboratory testing and point-of-care testing) with a user app and a clinician-facing remote monitoring dashboard. Distribution includes corporate contracts: the site notes revised terms of service for corporate customers and for corporate contract users, and reports that Toyoda Gosei adopted Provigate's "blood sugar management program" in 2025.

The site indicates services delivered to individual users (weekly mail-in or home POCT GA testing with app-based results) and to organizations under corporate service agreements, alongside grant and subsidy funding for R&D. Specific pricing is not disclosed.

Traction

Cumulative equity funding since founding was reported at 1.75 billion yen as of September 2021 and 1.85 billion yen as of January 2022, followed by a 2.0 billion yen round announced in October 2024. Commercial and validation signals include phased service launch from July 2023, adoption of the blood sugar management program by Toyoda Gosei (August 2025), participation in the OMEGA Study Group, an award for an outstanding presentation at the 28th Annual Meeting of the Japanese Telemedicine and Telecare Association (November 2024), and a peer-reviewed methods publication in Clinica Chimica Acta (2023).

Latest developments

In July 2026 the company announced a basic agreement to proceed with a capital and business alliance with Towns, described as a leading point-of-care testing company. In July 2026 it also announced, with Ozu Town and Japan Post, the start of social field testing of a regional health model as part of R&D under NEDO's Deep Tech Startup Support Fund / Deep Tech Startup Support Program (DTSU). Earlier, in 2025, it reported the establishment of a US subsidiary, held the OMEGA Meeting 2025, changed its corporate and service logos, and saw Toyoda Gosei adopt its blood sugar management program.